Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders: Results From a 6-Month, Multicenter, Open Study
The DOI matches its Crossref record.
Abstract
BACKGROUND: The goal of this study was to assess the efficacy and safety of risperidone in bipolar and schizoaffective disorders. METHOD: 541 patients entered this open, multicenter, 6-month study. Patients were entered provided that they fulfilled DSM-IV criteria for bipolar disorder or schizoaffective disorder, bipolar type, during a manic, hypomanic, mixed, or depressive episode. Risperidone was added to any previous mood-stabilizing medication that the patients were taking. Efficacy was assessed with the Young Mania Rating Scale (YMRS), the Hamilton Rating Scale for Depression (HAM-D), the Positive and Negative Syndrome Scale (PANSS), and the Clinical Global Impressions scale (CGI). Extrapyramidal symptoms (EPS) were assessed using the UKU Side Effect Rating Scale. RESULTS: 430 patients completed the study. Addition of risperidone produced highly significant improvements (p < .0001) on the YMRS and HAM-D at both 6 weeks and 6 months and on the CGI and the scales of the PANSS at both 4 weeks and 6 months. There was a significant reduction in UKU total and subscale scores at 6 months. The mean dose of risperidone was 3.9 mg/day. There was no single case of new-emergent tardive dyskinesia, and there was a very low incidence of exacerbation of mania within the first 6 weeks (2%). Adverse events were few and mostly mild. the most frequent being EPS and weight gain. CONCLUSION: This large study provides additional evidence that risperidone is effective and well tolerated when combined with mood stabilizers in the treatment of bipolar disorder and schizoaffective disorder, bipolar type. Previous concerns about exacerbation of manic symptoms were not confirmed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Belmaker, R. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035354 · Cited by 473
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Suppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Tohen, M., Chengappa, K. N. R., Suppes, T., Baker, R. W., Zarate, C. A., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Ghaemi, S. N., Feldman, P. D., et al. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.4.337 · Cited by 326
Metadata
- Authors
- Vieta, E., Goikolea, J. M., Corbella, B., Benabarre, A., Reinares, M., MartÌnez, G., Fernandez, A., Colom, F., Martinez-Aran, A., & Carla Torrent for the Group for the Study of Risperidone in Affective Disorders (GSRAD)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-10-15
- Volume
- 62
- Issue
- 10
- Pages
- 818-825
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2043577227
- Cited by
- 122
- References
- 0
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders: Results From a 6-Month, Multicenter, Open Study. https://app.cochat.ai/papers/10.4088/jcp.v62n1011
- The paper
- Vieta, E., Goikolea, J. M., Corbella, B., Benabarre, A., Reinares, M., MartÌnez, G., Fernandez, A., Colom, F., Martinez-Aran, A., & Carla Torrent for the Group for the Study of Risperidone in Affective Disorders (GSRAD). (2001). Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders: Results From a 6-Month, Multicenter, Open Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v62n1011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.